These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23407048)

  • 21. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
    Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
    Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.
    Santos NP; Callegari-Jacques SM; Ribeiro Dos Santos AK; Silva CA; Vallinoto AC; Fernandes DC; de Carvalho DC; Santos SE; Hutz MH
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):499-504. PubMed ID: 23394127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
    Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
    PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
    Ng CS; Hasnat A; Al Maruf A; Ahmed MU; Pirmohamed M; Day CP; Aithal GP; Daly AK
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1079-86. PubMed ID: 24888881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
    Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z
    Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study.
    Pourmohamadi N; Pour Abdollah Toutkaboni M; Hayati Roodbari N; Tabarsi P; Baniasadi S
    Iran J Med Sci; 2023 Sep; 48(5):474-483. PubMed ID: 37786472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.
    Yamada S; Tang M; Richardson K; Halaschek-Wiener J; Chan M; Cook VJ; Fitzgerald JM; Elwood RK; Brooks-Wilson A; Marra F
    Pharmacogenomics; 2009 Sep; 10(9):1433-45. PubMed ID: 19761367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
    An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
    Singla N; Gupta D; Birbian N; Singh J
    Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
    Huang YS; Chern HD; Su WJ; Wu JC; Chang SC; Chiang CH; Chang FY; Lee SD
    Hepatology; 2003 Apr; 37(4):924-30. PubMed ID: 12668988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
    Yuliwulandari R; Susilowati RW; Wicaksono BD; Viyati K; Prayuni K; Razari I; Kristin E; Syafrizal ; Subagyo ; Sri Diana E; Setiawati S; Ariyani A; Mahasirimongkol S; Yanai H; Mushiroda T; Tokunaga K
    J Hum Genet; 2016 Jun; 61(6):533-7. PubMed ID: 26911349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
    Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
    Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
    [No Abstract]   [Full Text] [Related]  

  • 33. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.
    Leiro-Fernandez V; Valverde D; Vázquez-Gallardo R; Botana-Rial M; Constenla L; Agúndez JA; Fernández-Villar A
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1403-8. PubMed ID: 22283902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
    Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
    PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
    Shi J; Xie M; Wang J; Xu Y; Liu X
    Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.
    Ohno M; Yamaguchi I; Yamamoto I; Fukuda T; Yokota S; Maekura R; Ito M; Yamamoto Y; Ogura T; Maeda K; Komuta K; Igarashi T; Azuma J
    Int J Tuberc Lung Dis; 2000 Mar; 4(3):256-61. PubMed ID: 10751073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
    Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
    Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.
    Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Sanchez C; Poterico JA; Tarazona-Santos E; Guio H
    Pharmacol Res Perspect; 2024 Jun; 12(3):e1179. PubMed ID: 38666760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects].
    Negri L; Le Grusse J; Séraissol P; Lavit M; Houin G; Gandia P
    Therapie; 2014; 69(6):509-16. PubMed ID: 25314930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.
    Higuchi N; Tahara N; Yanagihara K; Fukushima K; Suyama N; Inoue Y; Miyazaki Y; Kobayashi T; Yoshiura K; Niikawa N; Wen CY; Isomoto H; Shikuwa S; Omagari K; Mizuta Y; Kohno S; Tsukamoto K
    World J Gastroenterol; 2007 Dec; 13(45):6003-8. PubMed ID: 18023090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.